Last reviewed · How we verify
Carboplatin, 5FU concomitant
Carboplatin and 5-fluorouracil (5FU) work together as chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells.
Carboplatin and 5-fluorouracil (5FU) work together as chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells. Used for Head and neck cancer (squamous cell carcinoma), Locally advanced or metastatic head and neck cancer.
At a glance
| Generic name | Carboplatin, 5FU concomitant |
|---|---|
| Sponsor | Groupe Oncologie Radiotherapie Tete et Cou |
| Drug class | Chemotherapy combination (platinum agent + antimetabolite) |
| Target | DNA (carboplatin); thymidylate synthase (5FU) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing cell replication and triggering apoptosis. 5FU is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and also affecting RNA function. The combination is used concomitantly to enhance cytotoxic effects against cancer cells, particularly in head and neck malignancies.
Approved indications
- Head and neck cancer (squamous cell carcinoma)
- Locally advanced or metastatic head and neck cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Diarrhea
- Nephrotoxicity
- Ototoxicity
- Anemia
- Fatigue
Key clinical trials
- Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (PHASE3)
- Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
- PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC (EARLY_PHASE1)
- Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer (PHASE1, PHASE2)
- Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer (PHASE2)
- Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (PHASE3)
- A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer (PHASE2)
- A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |